PharmaJet, Invectys enter Phase 2 cancer vaccine trial
Needle-free injection technology company PharmaJet, based in Golden, Colo., will be working with French biopharma company Invectys to test Invectys' therapeutic cancer vaccine. The Phase 2 trial is for INVAC-1, which uses PharmaJet’s needle-free injection system and is an immunotherapeutic DNA vaccine meant to treat cancer, the companies said.
“We believe the PharmaJet Needle-free device offers many advantages to patients and providers including less pain and stress, elimination of needles and provides a more precise and consistent method for vaccine delivery,” Invectys CEO Pierre Langlade Demoyen said.
PharmaJet said that it has previously tested its Tropis needle-free injection system in huyman and animal clinical trials without evidence of safety concerns.
“We are pleased that the PharmaJet Tropis Intradermal device has been chosen as the method of administration for this important cancer immunotherapy vaccine development.” PharmaJet CEO and chairman Ron Lowy said. “The Needle-free device is safe, fast and easy to administer, and has already been used successfully in numerous clinical studies for nucleic acid (DNA or RNA) vaccine delivery.”
“We believe the PharmaJet Needle-free device offers many advantages to patients and providers including less pain and stress, elimination of needles and provides a more precise and consistent method for vaccine delivery,” Invectys CEO Pierre Langlade Demoyen said.
PharmaJet said that it has previously tested its Tropis needle-free injection system in huyman and animal clinical trials without evidence of safety concerns.
“We are pleased that the PharmaJet Tropis Intradermal device has been chosen as the method of administration for this important cancer immunotherapy vaccine development.” PharmaJet CEO and chairman Ron Lowy said. “The Needle-free device is safe, fast and easy to administer, and has already been used successfully in numerous clinical studies for nucleic acid (DNA or RNA) vaccine delivery.”